Lexeo Therapeutics Cuts Arrhythmia Burden by 80% in Genetic Heart Disease Study
Source: Benzinga ·

Lexeo Therapeutics Inc. (NASDAQ:LXEO) on Monday announced positive interim results from its ongoing HEROIC-PKP2 Phase 1/2 trial evaluating LX2020 in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) and outlined plans to launch a pivotal study in late 2027. PKP2-ACM is an inherited h
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.